ArticlePLoS pathogens2019
FOXO1 transcription factor plays a key role in T cell-HIV-1 interaction.
Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Epigenetic mechanisms of retroviral regulation: a comparative review.Epigenetics & chromatin · 2026Review
- Article
- HIV-induced T cell quiescence and the origins of viral latency.Nature immunology · 2025Article
- Modeling simian immunodeficiency virus (SIV) latency in primary rhesus macaque CD4bioRxiv : the preprint server for biology · 2025Article
- Heat shock protein 90 is a chaperone regulator of HIV-1 latency.PLoS pathogens · 2025Article
- Integrated bioinformatics analysis identifies hub genes and immune regulatory networks in HIV infection.Frontiers in immunology · 2025Article
- FOXO1 or not FOXO1: that is the question.Cancer communications (London, England) · 2025Article
- Aggravating mechanisms from COVID-19.Virology journal · 2024Review
- Role ofSaudi journal of biological sciences · 2023Article
- FOXP1 regulates oxidative stress, SIRT1 expression, and resistance to chemotherapies in acute myeloid leukemia cells.Blood advances · 2023Article
- An Evaluation on the Role of Non-Coding RNA in HIV Transcription and Latency: A Review.HIV/AIDS (Auckland, N.Z.) · 2023Review
- The diverse roles of miRNAs in HIV pathogenesis: Current understanding and future perspectives.Frontiers in immunology · 2022Review
- Epigenomic characterization of latent HIV infection identifies latency regulating transcription factors.PLoS pathogens · 2021Article
- Plasma Extracellular Vesicles Enhance HIV-1 Infection of Activated CD4Frontiers in immunology · 2021Article
- Convergent Functional Genomics approach to prioritize molecular targets of risk in early life stress-related psychiatric disorders.Brain, behavior, & immunity - health · 2020Review
- Human Norovirus Replication in Temperature-Optimized MDCK Cells by Forkhead Box O1 Inhibition.Journal of microbiology and biotechnology · 2020Article
- FOXO1 promotes HIV latency by suppressing ER stress in T cells.Nature microbiology · 2020Article
- Review
- SAMHD1 as the Potential Link Between SARS-CoV-2 Infection and Neurological Complications.Frontiers in neurology · 2020Review
- Targeting HIV-1 proviral transcription.Current opinion in virology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV-1 is dependent on the host cell for providing the metabolic resources for completion of its viral replication cycle. Thus, HIV-1 replicates efficiently only in activated CD4+ T cells. Barriers preventing HIV-1 replication in resting CD4+ T cells include a block that limits reverse transcription and also the lack of activity of several inducible transcription factors, such as NF-κB and NFAT. Because FOXO1 is a master regulator of T cell functions, we studied the effect of its inhibition on T cell/HIV-1 interactions. By using AS1842856, a FOXO1 pharmacologic inhibitor, we observe that FOXO1 inhibition induces a metabolic activation of T cells with a G0/G1 transition in the absence of any stimulatory signal. One parallel outcome of this change is the inhibition of the activity of the HIV restriction factor SAMHD1 and the activation of the NFAT pathway. FOXO1 inhibition by AS1842856 makes resting T cells permissive to HIV-1 infection. In addition, we found that FOXO1 inhibition by either AS1842856 treatment or upon FOXO1 knockdown induces the reactivation of HIV-1 latent proviruses in T cells. We conclude that FOXO1 has a central role in the HIV-1/T cell interaction and that inhibiting FOXO1 with drugs such as AS1842856 may be a new therapeutic shock-and-kill strategy to eliminate the HIV-1 reservoir in human T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.